Analyzing Enliven Therapeutics (NASDAQ:ELVN) & Aptorum Group (NASDAQ:APM)

Aptorum Group (NASDAQ:APM) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Institutional and Insider Ownership

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Aptorum Group and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Enliven Therapeutics	N/A	-29.15%	-27.88%

Earnings and Valuation

This table compares Aptorum Group and Enliven Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430,000.00	17.17	-$4.27 million	N/A	N/A
Enliven Therapeutics	N/A	N/A	-$89.02 million	($2.00)	-8.82

Aptorum Group has higher revenue and earnings than Enliven Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Aptorum Group and Enliven Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1	0	0	0	1.00
Enliven Therapeutics	1	0	5	0	2.67

Enliven Therapeutics has a consensus price target of $41.20, suggesting a potential upside of 133.69%. Given Enliven Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Aptorum Group.

Volatility and Risk

Aptorum Group has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.